Biological properties of Serratia liquefaciens 1/2024, isolated from chicken
pdf

Keywords

Antibiotic resistance
biofilm
pathogenicity
sequencing
Serratia spp.

How to Cite

VYGOVSKA , L., USHKALOV, A., ZELENA, L., USHKALOV, V., SÎRBU, C. and VISHOVAN, Y. (2025) “Biological properties of Serratia liquefaciens 1/2024, isolated from chicken: ”, One Health & Risk Management , 7(1), pp. 22-38. doi: 10.38045/ohrm.2026.1.03.

Abstract

Introduction. According to a study by the European Centre for Disease Prevention and Control (ECDC) for 2022-2023, Serratia spp. caused 54,406 cases of disease in 28 countries worldwide. Serratia liquefaciens is considered the second most frequently isolated organism from human clinical samples after Serratia marcescens. The aim of this study was to investigate the biological properties of S. liquefaciens isolated from chickens.

Materials and methods. The study investigated a Serratia liquefaciens strain isolated in 2024 from chickens kept in a vivarium with clinical manifestations of gastrointestinal tract disorders. The aim of the study was to examine the strain S. liquefaciens. When studying the biological properties of the isolate, morphological characteristics, growth typicality, biochemical properties, pathogenicity for laboratory animals, and antibiotic sensitivity were taken into account.

Results. The isolated microorganism formed colonies typical of the Serratin genus, and the cells were motile at 37°C. The enzymatic profile matched the known characteristics of S. liquefaciens. The strain produced a denser biofilm at 23°C, exhibited pathogenicity in white mice, and showed resistance to several classes of antimicrobial agents. Based on the sequencing of a 16S rRNA gene fragment, the strain was deposited in the NCBI GenBank database under accession number PQ308601.1.

Conclusions. The results obtained suggest that the S. liquefaciens 1/2024 may be used as a reference strain for the differential diagnosis of enterobacteria, assessment of antimicrobial activity, and application as a laboratory control strain in experimental studies.

https://doi.org/10.38045/ohrm.2026.1.03
pdf

|Views: 595| |pdf Downloads: 230|


pdf
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2025 Valerii Ushkalov

Downloads

Download data is not yet available.

ANNOUNCEMENT

Starting from July 1, 2025, the article processing fee will be 20 EUR (or the equivalent in MDL at the official exchange rate of the National Bank of Moldova). The publication fee for an accepted article will be 150 EUR (or the equivalent in MDL).

Details here:

Processing Fee
A processing fee of 20 EUR (or the equivalent in MDL) will be charged for articles accepted for scientific review by the editorial committee of the One Health and Risk Management journal.
Note: This fee will only be charged if your article has been technically reviewed and accepted.

Publication Fee
Starting from 01.07.2025, a fee of 150 EUR (or the equivalent in MDL) will be charged for articles accepted for publication.
Additionally, authors will bear the cost of English language editing/translation services if the manuscript requires intervention. The fee is 5 EUR (or the equivalent in MDL) per page edited/translated.
The total cost for English editing/translation services will be communicated by the Editorial Board after the manuscript is accepted for publication.

Payment Details:
Payments should be made in MDL to the bank account opened in the name of the Biosafety and Biosecurity Association of the Republic of Moldova.
The invoice will be issued by the end of the month in which the payment was made.

Organization: Biosafety and Biosecurity Association of the Republic of Moldova
Address: 5C A. Cozmescu Street
Fiscal Code: 1017620004120
Bank Code (SWIFT): AGRNMD2X451
IBAN: MD34AG000000022513622370